Implementing Complementary Treatments to Address the Pathophysiologic Processes of T2DM: Focus on GLP-1–based Therapies Webcast

Release date: January 8, 2016
Expiration date: January 8, 2017
Expected time to completion: 0.75 hour


Carol H. Wysham, MD
Associate Clinical Professor of Medicine
University of Washington
Seattle, Washington
Section Head
Department of Diabetes and Endocrinology
Rockwood Clinic
Spokane, Washington

Program Overview

Among patients with diabetes, approximately 95% are diagnosed with type 2 diabetes mellitus (T2DM) and the incidence of T2DM is increasing. The past two decades have witnessed a dramatic increase in the number of therapeutic agents available to treat patients with T2DM. With the wide range of options available, clinicians are faced with complex decisions regarding the optimal course of treatment. As T2DM has been revealed to be a disease characterized by dysfunction across multiple systems, a shift in approach has emphasized the importance of complementary treatment regimens that can address multiple processes simultaneously. In this context, glucagon-like-peptide-1 (GLP-1) has gained recognition as an important target for the treatment of T2DM.

When choosing a treatment regimen, clinicians must consider additional factors that can impact the probability of success. One of the most important factors is whether a patient is likely to adhere to a prescribed regimen. In light of this, the recent approval of agents that require less frequent dosing represents a significant development with the potential to improve outcomes for patients with T2DM. Presently, there are three long-acting GLP-1 receptor agonists that have been approved by the FDA that require only once-weekly dosing.

Target Audience

This educational initiative has been designed for endocrinologists, internal medicine physicians, fellows-in-training, residents, and other healthcare providers involved in the care of patients with T2DM.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Implement current evidence-based guidelines for the detection and diagnosis of prediabetes and diabetes
  • Describe the rationale for and role of GLP-1-based therapeutic strategies for treatment of patients with T2DM
  • Apply evidence-based and individualized management strategies to ensure responsiveness and appropriate glucose-lowering effects in patients with T2DM

Directions to Learner

There are no fees for participating and receiving CME credit for this activity. During the period January 8, 2016 through January 8, 2017, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
  • Complete the evaluation form

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be sent to you within 4 weeks.



Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Carol H. Wysham, MD

  • Consultant: AstraZeneca, Janssen, Sanofi
  • Speaker: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi
  • Research: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and AstraZeneca. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Minimum System Requirements

Windows XP, Windows 2000, Windows Vista, and Windows 7 Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.

Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10

Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

begin pretest


For optimal performance, the use of Internet Explorer is not recommended.


Sponsored by Integrity Continuing Education, Inc. 
Supported by an educational grant from AstraZeneca.